The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Table 2 Association between Recurrence Score results and disease outcomes

	5-year Kaplan-Meier risk estimate (%) and 95% CI by Recurrence Score group
Risk	Low (< 18)	Intermediate (18-31)	High (≥ 31)	HR per 50 units^* (95% CI)
DR	93.7 (89.4-96.3)	87.3 (81.0-91.6)	69.3 (61.5-75.8)	4.14 (2.67-6.43)
DR	p < 0.001^†			p < 0.001^§
DFS	90.8 (86.0-94.1)	84.9 (78.3-89.6)	64.6 (56.7-71.4)	3.28 (2.18-4.94)
DFS	p < 0.001^†			p < 0.001^§
OS	99.0 (96.2-99.8)	95.6 (90.9-97.9)	85.6 (79.1-90.2)	5.0 (3.01-8.28)
OS	p < 0.001^†			p < 0.001^§

DR distant recurrence, 95%CI 95% confidence interval, HR hazard ratio, DFS disease-free survival, OS overall survival
^*Recurrence Score was a continuous variable in a Cox proportional hazards regression model, with the HR adjusted for treatment and calculated relative to an increment of 50 units
^†p-value from log-rank test for comparison of entire Kaplan-Meier plots among the three Recurrence Score groups
^§p-value from Wald test for significance of HR

ISSN: 1471-2407